Kunshan ruiboquark pharmaceutical technology completed 45 million RMB round a financing to accelerate the clinical development of qpi-1007

Kunshan ruiboquark Pharmaceutical Technology Co., Ltd has completed a round of financing of 45 million yuan to accelerate the clinical development of qpi-1007 At present, the drug is carrying out phase III trials for the treatment of non arteritis anterior ischemic optic neuropathy and phase IIa trials for the treatment of glaucoma Qpi-1007 is a synthetic small nucleic acid drug (siRNA), which is used to block the expression of caspase-2, an apoptotic protein, and has the protective effect on optic nerve On September 12, 2012, Suzhou Rabo Biotechnology Co., Ltd and U.S quark Pharmaceutical Co., Ltd officially announced to become strategic partners, and established "Kunshan Rabo quark Pharmaceutical Technology Co., Ltd." to jointly promote clinical research focusing on RNAi drugs Reboq will become a leading clinical R & D pharmaceutical company at home and abroad, focusing on the development of RNAi based innovative drugs to meet the needs of patients in this treatment field RBQ will be located in the world-class RNAi biomedical industrial park in Kunshan City, Jiangsu Province Quark Pharmaceuticals and Suzhou Ribo Life Science   BVCF, China’s leading life sciences venture capital firm In addition to BVCF, investors in the financing included SBI Incubation Co., Ltd., a subsidiary of SBI Group of Japan, the Kunshan Industrial Technology Research Institute Investment Co., Ltd and Kunshan Hongtu Hi-tech Venture Capital Management Co., Ltd The proceeds of this capital raise will be used primarily to accelerate the clinical development of RiboQuark’s lead product, QPI-1007, an ocular neuroprotectant RiboQuark has licensed from Quark Pharmaceuticals to sell in China and several other countries QPI-1007 is entering global Phase III studies in non-arteritic anterior ischemic optic neuropathy (NAION) and a pilot Phase II study in acute angle closure glaucoma NAION is a devastating, incurable orphan disease, which is an entirely unmet medical need The only known treatment for angle closure glaucoma, which is a major cause of blindness worldwide, is surgical intervention In addition to the further clinical development of QPI-1007, this capital will enable RiboQuark to continue developing its broad pipeline of siRNA-based preclinical drug candidates, contributed by its two founders, for a wide range of diseases – including cancer, hepatitis and lung injury RiboQuark is also developing for the Chinese market a siRNA-based cosmetic product for the prevention of hair loss as a result of chemotherapy and radiation Dr Liang Zicai, Chairman of Ribo, commented, “The successful completion of this financing round is a strong demonstration of the confidence of our investors in the future of RNAi therapeutics and the ability of RiboQuark to lead this emerging drug class development in China and Asia RNAi technologies have progressed immensely in the last few years, creating a huge knowledge base that, I believe, will continue to grow This should allow the siRNA drugs to fulfill the promise to enable the treatment of a vast panel of diseases.” “We are glad to have the opportunity to lead this round of RiboQuark financing,” said Zhi Yang, Founding Partner and Chairman of BVCF, “We are confident that given the combination of the highly experienced management team between Ribo and Quark, the company is well positioned to deliver on the promise of RNAi therapeutics.” Dr Daniel Zurr, president and CEO of Quark Pharmaceuticals Inc said, “We are very excited that this financing allows us to accelerate the development of the breakthrough neuroprotective agent QPI-1007 Both NAION and angle closure glaucoma are devastating diseases characterized by the loss of retinal ganglion cells (RGCs), causing optical nerve damage and often leading to irreversible loss of vision Studies have shown that as many as 28 million people in China have a genetic predisposition for angle closure glaucoma, with 9 to 10 million people suffering from the disease We believe that the disease is similarly preva1ent throughout Asia, making the protection of RGCs an imp0rtant objective in the broader effort to increase overall ocular health in the region.” ab0ut QPI-1007 QPI-1007 is a synthetic siRNA designed to temporarily inhibit expressi0n of the pro-apoptotic protein, Caspase 2 QPI-1007 utilizes a novel siRNA structure developed by Quark that preserves activity while attenuating off-target and immunostimulatory effects Quark completed a phase I/IIa first in human, open label, single-dose, dose escalation, safety, tolerability and pharmacokinetic study of QPI-1007, conducted at 16 centers in the USA and 5 centers in Israel The study showed QPI-1007 was safe and exhibits strong neuroprotective activity in NAION patients Ribo Life Science Co., Ltd is an innovative R&D company devoted to the development of nucleic acid drugs and related products based on the RNA interference (RNAi) technology Ribo has built a strong strength in nucleic acid liquid-phase synthesis technology and production of nucleic acid crude drugs, and has developed some great drug R&D projects with its innovative R&D capabilities, aiming to make contribution to the treatment of serious diseases troubling the Chinese population Ribo’s founders include some of China’s most renowned scientists in the field of RNAi technology Ribo received the prize of The First Innovative Team in Jiangsu China Ribo is headquartered in Kunshan, Jiangsu Province and has a subsidiary in Beijing For more information, please visitwww.ribolia.com Quark Pharmaceuticals, Inc., the world leader in novel RNAi discovery and development, has the largest clinical-stage siRNA pipeline in the industry The Company’s fully integrated drug development platform spans therapeutic target identification to drug development Quark’s approach to delivery allows targeting of tissues and organs including the eye, kidney, ear, lung, skin, spinal cord and brain Quark has a rich pipeline of siRNA drug candidates in six different indications, which completed proof of concept in a variety of animal models conducted by renowned opinion leaders It has three product candidates in clinical development in five different indications of which four are in phase II and one in phase IIb Quark is part of the SBI Group, Japan, and is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel For additional information pl visit: www.quarkpharma.com BVCF (http://bvcf.com/, formally known as BioVeda China) is the first and go-to private equity and growth capital investor specializing in China Life Sciences and Healthcare industry Headquartered in Shanghai, BVCF’s team includes partners with premier academic background and extensive operational experience Investors include institutional limited partners and leading MNC pharmaceutical companies BVCF focuses on investment in mid-market (US$ 50 – 100 million enterprise value) Life Science and Healthcare companies in China The BVCF team takes an active approach with all of its investments, The target portfolio company for bvcf is profiled to be a mid to late stage company as a top player in its sector with capable trustworthy management teams and strong growth potential Qpi-1007 next article: Yiteng pharmaceutical and act biotech reach an agreement to buy telatinib, actb1003 and actb1010 three new drugs for global licensing last article: probiodrug transfers the experimental cyclin dependent kinase 9 (CDK9) inhibitor project to AstraZeneca [new drug express search] [addfav ('add to collection ');] [tell friends] [print this article ][close window] 0 relevant reports [view all] relevant comments in total Recommended graphic ly09004 is approved to enter the first clinical 2019 new year order! Deqi medical's first domestic PD-1 was approved for market priority review and encouraged children's drug research / * 300 * 250, which was founded on May 8, 2014 * / var cpro_id = "u1548962"; the recommended new drug express ly09004 was approved for clinical use, and LVYE pharmaceutical accelerated the global distribution of biological drugs in 2019 New Year's first single! Deqi Pharmaceutical Co., Ltd has completed 120 million USD round B financing and launched the first domestic PD-1 of the original research and innovation drug platform layout of cancer to be approved for listing! Facing the price test! Give priority to review and encourage the outbreak of children's drug research and development! 16 of the 46 new drugs have been approved for Q4 sprint: important products of famous enterprises such as Hengrui, Fosun, hausen, Huahai, dongyangguang and XinDa will be sold to promethazine API giants! Erkang pharmaceutical becomes an oligarch! Hengrui, Zhengda Tianqing anti-tumor drug price negotiation succeeded! Will the sales of androtini exceed 1 billion this year? In 2018, these 49 drugs were modified in the instruction manual, 23 injections were eye-catching, and a large number of drug children were forbidden to use "R & D first brother" to change owners? Half a year's R & D investment is nearly 1.2 billion yuan This pharmaceutical company may be the first car-t in China In 2018, three domestic tinies will be listed one after another Who will become the fourth approved domestic Tinian in the year? "Viewtext": "shared to:", "viewsize": "16"}, "selectShare":{"bdContainerClass":null,"bdSelectMiniList":["qzone","tsina","tqq","renren","t163"]}};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')).src='http://bdimg.share.baidu.com/static/api/js/share.js?v=86835285.js?cdnversion='+~(-new Date()/36e5)];   New drug sinks WeChat Website homepage | member upgrade |About our | contact information | service team | use agreement | copyright privacy | remittance account | website map |Website message | advertising service | RSS subscription #powered h1{font-size:12px;display:inline;}#powered h2{font-size:12px;display:inline;} New drug pool is a professional platform for new drug technology service and achievement transfer, providing new drug clinical approval, new drug certificate transfer, new drug outsourcing technology service information! New drug transfer, new drug R & D - new drug pool Marketing cooperation / member upgrading / Advertising Hotline: 025-58847012 © new drug huixinyaohui.com Nanjing Maituo Pharmaceutical Technology Co., Ltd all rights reserved var cnzz \ u protocol = ("HTTPS:" = = document Location Protocol)? "HTTPS: / /:" http: / / "); document.write (unescape (" "% 3cspan id ='cnzz \ u stat \ Icon \ u 5745669 '% 3